flovent hfa Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Flovent Hfa, and when can generic versions of Flovent Hfa launch?
Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has twenty-nine patent family members in seventeen countries.
The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flovent Hfa
A generic version of flovent hfa was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for flovent hfa?
- What are the global sales for flovent hfa?
- What is Average Wholesale Price for flovent hfa?
Summary for flovent hfa
International Patents: | 29 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 38 |
Patent Applications: | 5,456 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for flovent hfa |
Drug Sales Revenues: | Drug sales revenues for flovent hfa |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for flovent hfa |
DailyMed Link: | flovent hfa at DailyMed |
![flovent hfa drug patent expirations Drug patent expirations by year for flovent hfa](/p/graph/s/t/flovent_hfa-patent-expirations.png)
![Drug Prices for flovent hfa](/p/graph/drug-price/flovent+hfa.png)
See drug prices for flovent hfa
![Drug Sales Revenue Trends for flovent hfa](/p/graph/drug-sales-revenues/flovent+hfa.png)
Recent Clinical Trials for flovent hfa
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Glenmark Pharmaceuticals Ltd. India | Phase 3 |
Children's Hospital Medical Center, Cincinnati | Phase 2 |
Respirent Pharmaceuticals Co Ltd. | Phase 1 |
Pharmacology for flovent hfa
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for FLOVENT HFA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FLOVENT HFA | Inhalation Aerosol | fluticasone propionate | 0.22 mg/inh | 021433 | 1 | 2021-10-29 |
FLOVENT HFA | Inhalation Aerosol | fluticasone propionate | 0.11 mg/inh | 021433 | 1 | 2016-12-23 |
US Patents and Regulatory Information for flovent hfa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-003 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for flovent hfa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-002 | May 14, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-003 | May 14, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-003 | May 14, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for flovent hfa
See the table below for patents covering flovent hfa around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 0020538 | ⤷ Sign Up | |
Australia | 7142994 | ⤷ Sign Up | |
African Intellectual Property Organization (OAPI) | 9926 | ⤷ Sign Up | |
Germany | 122006000020 | ⤷ Sign Up | |
Cyprus | 2401 | Metered dose inhaler for fluticasone propionate. | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for flovent hfa
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1519731 | 13C0067 | France | ⤷ Sign Up | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
2506844 | 132018000000341 | Italy | ⤷ Sign Up | PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117 |
2506844 | 2018C/022 | Belgium | ⤷ Sign Up | PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
1305329 | 08C0014 | France | ⤷ Sign Up | PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111 |
1519731 | 92269 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |